BioVendor Group Introduces Groundbreaking Immunological Biomarker
|
By LabMedica International staff writers Posted on 13 Nov 2024 |

At this year’s MEDICA, BioVendor Group (Brno, Czech Republic) is showcasing its impressive diagnostic innovations, from CLIA advancements to the groundbreaking MxA biomarker, which plays a key role in distinguishing between bacterial and viral infections.
BioVendor Group is fitting all group companies into a shared exhibition space at MEDICA 2024 and creating a welcoming environment for hundreds of meetings with new and existing business partners, customers, and suppliers. Visitors to the shared BioVendor Group booth can learn about several other product news and innovations from the companies BioVendor Research & Diagnostic Products, TestLine Clinical Diagnostics s.r.o., ViennaLab Diagnostics, DIAsource ImmunoAssays S.A. and BioVendor MDx. The main "drivers" are again the key projects CLIA, MBA, and NGS, developed in synergy by the various companies of the BioVendor Group. BioVendor is introducing brand-new micro-array kits from TestLine Clinical Diagnostics for the diagnosis of liver and gastrointestinal autoimmune diseases. Also featuring at the show is BioVendor MDx’s NGS fastGEN technology which offers rapid and accurate genetic analysis, enabling efficient cancer diagnostics. BioVendor MDx’s fastGEN BCR::ABL1 cancer kit specifically detects fusion genes associated with leukemia, supporting early diagnosis and treatment management. In addition to these innovations, visitors can also learn more about BioVendor MDx’s bioinformatics solution GENOVESA which is designed for seamless data interpretation and reporting.
DIAsource is announcing the addition of a new rapid test (POCT) and its respective reader to the company’s portfolio. These products complete the company’s panel with additional technologies and interesting parameters in the fields of women’s health, tumor markers, drugs of abuse, infectious diseases, cardiac markers. DIAsource is also launching a series of new antibodies in the fields of Alzheimer's disease, cardiac markers, diabetes and fertility. These antibodies have proven to be reliable raw materials in the manufacturing of immunoassays such as CLIA, ELISA, FIA, and POCT. BioVendor RnD is showcasing its extensive portfolio of ELISA kits for both research and diagnostic applications. In addition to its high-quality ELISA kits, the company is highlighting its high-purity proteins and a broad range of antibodies. BioVendor RnD is also presenting the MxA Point-of-Care-Test designed for the rapid differentiation between bacterial and viral infections. Visitors to the shared BioVendor Group booth can also learn about ViennaLab’s upcoming SMA RealFast Assay, comprehensive OncNGS (liquid biopsy (cfDNA) NGS solution), 16S Microbiome + ITS NGS Assay.
Related Links:
BioVendor Group
Latest Medica 2024 News
- EDAN Instruments Highlights Range of Lab Analyzers, ECG Devices and Ultrasound Systems
- Getein Biotech Showcases Latest POCT Analyzers
- Fapon Highlights Innovative IVD Total Solutions and Localization Services
- Wondfo Presents Advanced Solutions in CLIA Testing and Blood Gas Analysis
- Globe Scientific Exhibits Cutting-Edge Solutions for Meeting Laboratory Needs
- LGC Clinical Diagnostics Presents Seraseq and ACCURUN Range of Diagnostic Solutions
- Oruba Showcases Innovative Self-Operating Uroflowmeter
- Awareness Technology Showcases Range of Cutting-Edge Analyzers
- Sentinel Diagnostics Presents Latest Breakthroughs in Diagnostics
- Alcor Scientific Presents Latest Innovation in High Volume ESR Testing
- CerTest Showcases Latest Innovations in Diagnosis of Infectious Diseases
- Vircell Presents Latest Offerings and Products in Diagnostic Testing
- Tianlong Demonstrates Latest Biochemistry, Immunology, POCT and Molecular Diagnostic Products
- EKF Presents Cutting-Edge Point-Of-Care Diagnostic Solutions
- Vedalab Exhibits Rapid Diagnostic Tests
- Meridian Showcases Innovative Solutions for Molecular Diagnostics and Immunoassays
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








